The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Energy and protein intake
研究概览
简要总结
Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.
详细描述
Randomization of consecutive patients who wanted to participate to a daily dose of CBD or not as a supplement to the standard treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult, palliative pancreatic cancer diagnosis, weight loss > 5%, understand and read Danish.
排除标准
- •Regular use of cannabis, psychiatric disorders, alcohol abuse, life expectancy < 6 months
研究组 & 干预措施
THC and CBD Mixture
32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
干预措施: THC and CBD Mixture (Drug)
结局指标
主要结局
Energy and protein intake
时间窗: The outcome measure will be assessed at day 0 and at week 4
Dietary history (% of estimated needs - NRS 2002)
次要结局
- Lean body mass(The outcome measure will be assessed at day 0 and at week 4)
- Appetite 1(The outcome measure will be assessed at day 0 and at week 4)
- Appetite 2(The outcome measure will be assessed at day 0 and at week 4)
- Appetite 3(The outcome measure will be assessed at day 0 and at week 4)
- Appetite 4(The outcome measure will be assessed at day 0 and at week 4)
- Quality of life 1(The outcome measure will be assessed at day 0 and at week 4)
- Quality of life 2(The outcome measure will be assessed at day 0 and at week 4)
- Quality of life 3(The outcome measure will be assessed at day 0 and at week 4)
- Pain 1(The outcome measure will be assessed at day 0 and at week 4)
- Pain 2(The outcome measure will be assessed at day 0 and at week 4)
- Pain 3(The outcome measure will be assessed at day 0 and at week 4)
- Mortality (8 weeks)(8 weeks)
研究者
Jens Rikardt Andersen
Associate Professor
University of Copenhagen